Targeting MSLN for immunotherapy is based on observations of increased MSLN-specific antibodies detected in sera of about 40% of patients with mesothelioma and 42% of patients with ovarian cancer, indicating that antibody responses to MSLN was correlated with higher expression levels of MSLN on the surface of cancer cells (12). This evidence concerns the gene MSLN and ovarian cancer.